Related Experiment Video
Updated: Aug 5, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group
D M Green1, Y A Grigoriev, B Nan
1Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. daniel.green@roswellpark.org
Purpose:
We determined the frequency of and risk factors for congestive heart failure following treatment for Wilms' tumor that included doxorubicin.
Patients And Methods:
Flow sheets and medical records were reviewed to identify cases of congestive heart failure in a cohort of patients treated on National Wilms' Tumor Studies (NWTS)-1, -2, -3, and -4. The frequency of congestive heart failure was estimated using the Kaplan-Meier method. A case-control study was conducted to determine the relationship among cumulative doxorubicin dose, site(s), total dose of abdominal and thoracic irradiation, sex, and the frequency of congestive heart failure.
Results:
The cumulative frequency of congestive heart failure was 4.4% at 20 years after diagnosis among patients treated initially with doxorubicin and 17.4% at 20 years after diagnosis among those treated with doxorubicin for their first or subsequent relapse of Wilms' tumor. The relative risk (RR) of congestive heart failure was increased in females (RR = 4.5; P =.004) and by cumulative doxorubicin dose (RR = 3.3/100 mg/m(2); P <.001), lung irradiation (RR = 1.6/10 Gy; P =.037), and left abdominal irradiation (RR = 1.8/10 Gy; P =.013).
Conclusion:
We conclude that congestive heart failure is a risk of treatment with doxorubicin for Wilms' tumor. Additional follow-up of those children treated on NWTS-4 will be necessary to determine if the decrease in dose to 150 mg/m(2) significantly reduces this risk.
Related Concept Videos
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management

